PharmaTher Holdings Ltd. Stock

Equities

PHRM

CA71716H1082

Pharmaceuticals

Market Closed - Canadian Securities Exchange 03:45:48 2024-06-05 pm EDT 5-day change 1st Jan Change
0.22 CAD 0.00% Intraday chart for PharmaTher Holdings Ltd. +7.32% -30.16%
Sales 2022 - Sales 2023 - Capitalization 9.7M 13.27M
Net income 2022 -4M -5.47M Net income 2023 -6M -8.21M EV / Sales 2022 -
Net cash position 2022 12.12M 16.59M Net cash position 2023 6.25M 8.56M EV / Sales 2023 -
P/E ratio 2022
-3 x
P/E ratio 2023
-1.51 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 81.31%
More Fundamentals * Assessed data
Dynamic Chart
PharmaTher's Sairiyo Submits Clinical Trial Application in Australia For Phase 1 Study of Reformulated Cepharanthine MT
PharmaTher Assigned FDA Approval Goal Date for its New Drug Application for Ketamine MT
PharmaTher Brief: Announcing Assigned FDA Approval Goal Date of its Priority Original Abbreviated New Drug Application for Ketamine MT
PharmaTher Holdings Ltd. Announces Assigned FDA Approval Goal Date of its Priority Original Abbreviated New Drug Application for Ketamine CI
PharmaTher's Sairiyo Therapeutics Completes Regulatory Package For Phase 1 Study of Reformulated Cepharanthine in Australia MT
PharmaTher Holdings Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended February 29, 2024 CI
PharmaTher Updated on its Priority Original Abbreviated New Drug Application for Ketamine MT
PharmaTher Holdings Ltd. Provides Update of Its Priority Original Abbreviated New Drug Application for Ketamine CI
PharmaTher Provides Update For PD-001 MT
PharmaTher Provides Update on its Priority Original Abbreviated New Drug Application For Ketamine MT
PharmaTher Holdings Ltd. Provides Update of Its Priority Original Abbreviated New Drug Application for Ketamine CI
PharmaTher Holdings Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended November 30, 2023 CI
PharmaTher Provided Update for Expected FDA Approval of Ketamine MT
PharmaTher Holdings Ltd. Provides an Update for Its Lead Drug, Ketamine CI
PharmaTher Holdings Ltd. Reports Earnings Results for the First Quarter Ended August 31, 2023 CI
More news
1 week+7.32%
Current month+2.33%
1 month-10.20%
3 months+4.76%
6 months+29.41%
Current year-30.16%
More quotes
1 week
0.19
Extreme 0.19
0.23
1 month
0.19
Extreme 0.19
0.30
Current year
0.17
Extreme 0.17
0.43
1 year
0.08
Extreme 0.08
0.43
3 years
0.06
Extreme 0.055
1.24
5 years
0.05
Extreme 0.05
1.24
10 years
0.05
Extreme 0.05
1.24
More quotes
Managers TitleAgeSince
Chief Executive Officer - 19-12-31
Director of Finance/CFO 53 20-05-31
Corporate Officer/Principal - -
Members of the board TitleAgeSince
Director/Board Member - 20-05-31
Chief Executive Officer - 19-12-31
Director/Board Member - 20-05-31
More insiders
Date Price Change Volume
24-06-05 0.22 0.00% 38,790
24-06-03 0.22 +2.33% 67,305
24-05-31 0.215 +4.88% 52,500
24-05-30 0.205 0.00% 23,146
24-05-29 0.205 +5.13% 48,700

Delayed Quote Canadian Securities Exchange, June 05, 2024 at 03:45 pm EDT

More quotes
PharmaTher Holdings Ltd. is a Canada-based specialty pharmaceutical company. The Company develops and commercializes specialty pharmaceuticals exhibiting growing adoption and permitting delivery methods to enhance patient outcomes. Its lead product is KETARX (racemic ketamine) to fill the global unmet medical needs for anesthesia, sedation, pain, mental health, and neurological indications. The Company is also commercializing PharmaPatch (microneedle patch) with its partners to deliver psychedelics and drugs to treat infectious diseases.
More about the company

Quarterly revenue - Rate of surprise